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Abstract. The primary objective of this review was to update and discuss the current concepts and 
the results of the treatment of acute lymphoblastic leukemia (ALL) in adolescents and young adults 
(AYA). After a brief consideration of the epidemiologic and clinicobiologic characteristics of ALL 
in the AYA population, the main retrospective comparative studies stating the superiority of 
pediatric over adult-based protocols were reviewed. The most important prospective studies in 
young adults using pediatric inspired or pediatric unmodified protocols were also reviewed 
emphasizing their feasibility at least up to the age of 40 yr and their promising results, with event-
free survival rates of 60-65% or greater. Results of trials from pediatric groups have shown that the 
unfavourable prognosis of adolescents is no more adequate. The majority of the older adolescents 
with ALL can be cured with risk-adjusted and minimal residual disease-guided intensive 
chemotherapy, without stem cell transplantation. However, some specific subgroups, which are 
more frequent in adolescents than in children (e.g., early pre-T, iAMP21, and BCR-ABL-like), 
deserve particular attention. In summary, the advances in treatment of ALL in adolescents have 
been translated to young adults, and that explains the significant improvement in survival of these 
patients in recent years.  
Introduction. Acute lymphoblastic leukemia (ALL) 
encompasses a heterogeneous group of disorders. The 
results of clinical trials in adults have been 
disappointing compared with those of the pediatric age 
group, with cure rates of 90% in children compared 
with 30%–40% in adults
1
. An analysis of the 
Surveillance, Epidemiology, and End Results (SEER) 
database showed an improvement in survival in adults 
over the last two decades, with the greatest significant 




ALL is relatively rare among the AYA populations, 
whereas it is the most commonly diagnosed leukemia 
in childhood, accounting for 75% of leukemias 
diagnosed in pediatric patients. Many retrospective 
analyses of the adolescent age group with newly 
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diagnosed ALL treated according to either pediatric or 
adult protocols showed a statistically significantly 
superior outcome for patients treated with pediatric 
regimens. A lower relapse rate accounted for the 
superior results observed in adolescents treated 
according to pediatric protocols. For that reason, 
treatment of ALL in AYA has gained increasing 
interest in recent years. This review will focus on the 
biology and treatment of ALL in AYA.  
 
The Concept of AYA.  Although there is not a 
uniformly accepted definition of age subgroups in 
ALL, it can be considered that classic pediatric ALL 
patients range from 0 to14 yr of age, adolescents from 
15 to19 years, young adults from 20 to 39 years, adults 
from 40 to 60 years and older adults and elderly 
patients include those beyond the age of 65 years. 
Thus, AYA encompasses those patients from 15 to 39 
years of age. 
 
Biological Factors in ALL of AYA. Several clinical 
and biologic characteristics of ALL used for risk 
stratification and prognostication (e.g., phenotype, 
cytogenetics and molecular genetics) are age-
dependent (Table 1). Regarding the 
immunophenotype, T-cell ALL (T-ALL) is more 
frequent in AYA than in children and is known to be 
associated with slightly poor outcomes. In addition, the 
“early T-cell precursor ALL” (ETP-ALL) subtype, 
which is associated with poor treatment response, is 
frequently presented in AYA.
4 
One of the substantial differences between children 
and AYA is the difference in cytogenetics and 
molecular genetics. The genetic abnormalities 
associated with good prognosis decrease with age. 
Hyperdiploidy and the t(12;21) [ETV6-RUNX1] 
translocation decrease with older age,
5
 during poor-risk 
cytogenetics, such as t(9;22) [BCR-ABL1], complex 
karyotype, and hypodiploidy increase in prevalence 
with age. In addition, several reports have 
demonstrated that good risk cytogenetics is associated 
with inferior survival in adults and in adolescents 
compared with children.
6
 A recent study including a 
large cohort of teenagers and young adults enrolled in 
the UKALL2003 and UKALLXII trials showed a 
higher frequency of IgH@ translocations in AYA.
7
 
Although these translocations are associated with an 
adverse outcome in adults, they are not independent 
prognostic factors in children and adolescents.  
To date, there has been no specific study of 
genomic profiling of AYA with ALL because these 
patients have been included in both pediatric and adult 
ALL studies. However, JAK mutations, CRLF2 
alteration, iAMP21 and BCR-ABL-like profile are 
among the frequent alterations reported in AYA, and 
all of them are associated with a poor prognosis. In 
summary, the genetic profile of AYA ALL patients 
seems to be similar to patients with high-risk ALL, 
suggesting that distinct underlying genetic and biologic 
characteristics account for part of the inferior results 
observed in AYA.
8 
In addition to the difference in biological factors 
between ALL in children and in AYA, there is 
evidence that adult ALL cells are less susceptible to 
chemotherapy both in vitro and in vivo. In some studies 
ALL patients between 15–30 years of age had a 
significantly higher minimal residual disease (MRD) 
burden compared with children.
9,10 
As far as host factors are concerned, several features 
are present in less young patients, being responsible for 
increased treatment toxicity. They include differences 
in the metabolism of chemotherapeutic agents, depleted 
marrow reserve and increased extramedullary toxicity. 
All these issues increase the frequency of life-
threatening infections, organ failure, treatment delays 
and dose reductions in planned chemotherapy. 
 
Pediatric-based vs. Adult-based Treatments. 
Retrospective Studies. Several retrospective reports 
have shown that adolescents (15- 20 yr.) and young 
adults treated by adult oncologists or hematologists 
with adult ALL protocols have poorer outcomes than 
similarly aged patients treated by pediatricians with 
pediatric protocols despite having the same biologic 
disease.
11-20
 The cut-off point of age for treatment of 
patients in pediatric or adult hemato-oncology units 
varies among different countries but usually ranges 
between 15 and 18 years. 
Table 1. Biological features in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) 
Characteristic Comment 
Cytogenetics Low incidence of: hyperdiploidy, t(12;21) 
High incidence of: hypodiploidy, t(9;22), other poor risk cytogenetics, IgH@ translocations, 
complex karyotype 
Molecular genetics Increased frequency of mutations of: CRLF2, JAK, IKZF1, CDNK2A/B 
High incidence of: IAMP21 ,BCR-ABL-like 
Immunophenotype Higher incidence of early T precursor ALL 
Response to chemotherapy Higher MRD burden after induction chemotherapy 
Tolerabilty to intensive 
chemotherapy Poorer in some studies 
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The first study, in which such different outcomes 
were reported, was conducted in France.
12
 A 
comparison of AYA aged 15-20 yr, treated with the 
pediatric-based protocol FRALLE-93 (n=77) with 
patients of the same age and comparable clinical and 
biologic characteristics of ALL, who received the 
adult-based protocol LALA-94 (n=100), showed a 
complete remission (CR) rate of 94% vs. 83%, 
respectively. After a median follow-up of 3.5 yr, the 
supposed event-free survival (EFS) was 67% vs. 41% 
at 5 years. Multivariate analysis showed an 
independent influence of the protocol on the outcome. 
The differences in the drugs employed and, especially 
in the dose-intensity, might explain the better results of 
the FRALLE-93 protocol. In this protocol the 
cumulated dose of prednisone was five-fold higher, the 
vinca alkaloids three-fold and the asparaginase 20 fold-
higher than in the LALA-94 study. In addition, in the 
FRALLE-93 study the dose of prednisone in induction 
was higher, and asparaginase was also given in this 
period, in contrast with the LALA-94 trial. Moreover, 
the time interval between CR and post-remission 
therapy was 2 days in the FRALLE-93 vs. 7 days in the 
LALA-94 study. 
The North-American Cancer and Acute Leukemia 
Group B (CALGB) and the Children’s Cancer Group 
(CCG) performed a retrospective comparison of 
presenting features, planned treatment, CR rate, and 
outcome of 321 AYA, aged 16 to 20 years, which we 
treated in consecutive trials in either the CCG or the 
CALGB from 1988 to 2001.
11
 CR rates were identical, 
being 90% for both the CALGB and CCG AYA. The 
CCG AYA had a 63% EFS and 67% overall survival 
(OS) at 7 years in contrast to the CALGB AYA, in 
which the 7-year EFS was only 34%, and the OS was 
46%. While the CALGB AYA aged 16 to 17 years 
achieved similar outcomes to all the CCG AYA with a 
7-year EFS of 55%, the EFS for 18- to 20-year-old 
CALGB patients was only 29%. Comparison of the 
regimens showed that the CCG AYA received more 
intensive central nervous system prophylaxis and 
higher cumulative doses of non myelosuppressive 
agents earlier. There were no differences in outcomes 
in those who reached maintenance therapy on time 
compared with those who were delayed. 
A similar Dutch study in patients aged 15-21 yr 
yielded similar results,
13
 with a 5-yr EFS of 69% for 
comparable patients treated with the most dose-
intensive pediatric protocol DCOG vs. 34% for those 
treated with adult protocols ALL-5 and ALL-18 from 
the HOVON Group. Likewise, comparative 
retrospective studies from Italy also showed a poorer 
prognosis for patients aged 14-18 yr treated with adult-
type protocols.
14
 In turn, a Swedish study compared 
patients aged 10-40 yr treated with the pediatric trial 
NOPHO-92 (n=144) vs. a similar group of patients 
included in the Swedish Adult ALL Group (n=99).
15
 
Significantly higher CR rate (99% vs. 90%) and EFS 
were observed in patients treated with the pediatric 
protocol, with the type of treatment being an 
independent prognostic variable on multivariate 
analysis. However, it is of note that adults aged 26-40 
yr had significantly poorer prognosis than AYA (15-25 
yr). Another study from Denmark yielded similar 
results.
16
 In a retrospective study from the British 
Medical Research Council (MRC),performed only in 
adolescents (15-17 yr), who were enrolled in the 
ALL97/revised99 (pediatric, n=61) or 
UKALLXII/E2993 (adult, n = 67) trials between 1997 
and 2002 (17), the EFS (65% vs. 49%) was higher, and 
the rate of death in remission was lower in patients 
enrolled in the pediatric trial.
17
 In a retrospective study 
conducted in the Princess Margaret Hospital of Toronto 
restricted to AYA with T-ALL 40 patients (median age 
30 yr, range 17-69) were treated with several adult type 
protocols and were compared with 32 patients (median 
age 32 yr, range 17-64) treated with a DFCI protocol.
18
 
Although there were no differences in CR attainment 
(93% vs. 84%), the OS and relapse-free survival (RFS) 
probabilities were significantly higher in patients 
treated with the DFCI trial (83% vs. .56% and 88% vs. 
23%, respectively). On multivariate analysis the 
treatment group (DFCI vs. non-DFCI) was the major 
prognostic factor influencing both RFS and OS. Other 
studies from different countries 
19
 have shown similar 
results (Table 2).  
Table 2. Retrospective comparative studies in adolescents and 
young adults with acute lymphoblastic leukemia treated with 
pediatric (P) vs. adult-based (A) protocols. 
Country 
(reference) 





USA (11) CCG(P)  16-20  197 90 63 
 
CALGB(A)   124 90 34 
France (12)  FRALLE93(P)  15-20  77 94 67 
 
LALA94 (A)   100 83 41 
Holland (13)  DCOG (P) 15-18  47 98 69 
 
HOVON (A)   44 91 34 




95 89 71 




99 90 48 




67 94 49 




20 80 40 
Finland (20) NOPHO (P) 10-25 128 96 67 
 
ALL (A)   97 97 60 
N: number of patients; CR: complete remission. EFS: event-free 
survival 
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Only one population-based study from Finland 
showed that the outcomes of AYA with ALL treated 
with pediatric or adult protocols were equal.
20
 One 
hundred and twenty-eight patients (10-16 yr.) were 
treated with the pediatric Nordic (NOPHO) protocols 
and 97 patients (17-25 yr.) with Finnish Leukemia 
Group National protocols. All patients were centrally 
referred and treated in five academic centers. The 5-
year EFS was 67% for the pediatric treatment group 
and 60% for the adult treatment group. There were no 
significant differences in the cumulative doses of 
corticosteroids, vincristine and asparaginase between 
the pediatric and adult protocols, whereas the pediatric 
protocols used a higher cumulative dose of 
methotrexate and lower doses of anthracyclines than 
the adult protocols. Epipodophyllotoxins and 
mitoxantrone were not included in the pediatric 
protocols. The authors attributed the similar results to 
the similarity of the pediatric and adult protocols and to 
the centralized care of the patients in five academic 
centers, ensuring good compliance and adherence to 
the protocols in both the two distinct age groups.  
Finally, the retrospective data from the MD 
Anderson Cancer Center using the Hyper-CVAD 
regimen (not including asparaginase) have also 
reported favorable results in 102 AYA (median age 19 
yr), with CR of 97% and OS of 65%. Preliminary 
reports from 60 AYA patients aged 12-40 yr treated at 
the MD Anderson Cancer Center with modified 
augmented Berlin-Frankfurt-Münster (BFM) therapy 
showed very promising results (2-yr DFS and OS 
probabilities of 85% and 91%, respectively) in the 
subset of patients younger than 25 yr,
21
 stressing the 
importance of treating these patients in large referral 
centers. 
In summary, the 5- to 6-yr EFS rate for AYA 
treated with pediatric regimens ranges from 65% to 
70% vs. 35% to 50% for adult regimens in almost all 
retrospective comparative studies. However, it is of 
note that the former included adolescents with a 
median age 16 or 17 yr. and the latter were adolescents 
and young adults with a median age 19 yr. or more. On 
the other hand, all the studies mentioned above have 
focused on patients aged 15-21 years, but few have 
evaluated the results in young adults up to 30 years or 
more, in which the frequency of patients with adverse 
prognostic factors is progressively increasing. 
A meta-analysis of trials was conducted comparing 
AYA patients treated with pediatric versus adult 
regimens.
22
 This meta-analysis included a total of 11 
such trials and 2489 patients. The AYA patients treated 
with pediatric regimens had significantly lower all-
cause mortality at three years (relative risk [RR] 0.58, 
0.51–0.67). The CR rate was significantly higher when 
AYA patients received the pediatric regimen (RR 1.05, 
1.01–1.1), and there was a significant improvement in 
the 3-year EFS (RR 1.66, 1.39–1.99). The relapse rate 
was also lower in patients receiving pediatric-inspired 
regimens (RR 0.51, 0.39-0.66) with similar non-relapse 
mortality (RR 0.53, 0.19-1.48). 
Several factors may have contributed to explain this 
different outcome, which cannot be exclusively 
interpreted in view of some existing differences in the 
distribution of prognostic factors between the 
populations enrolled in pediatric and adult trials. A 
major role is certainly played by differences in protocol 
design and treatment intensity, with pediatric protocols 
including more non myelosuppressive drugs with 
demonstrated activity on ALL blasts, such as 
asparaginase, glucocorticoids and vincristine. 
Moreover, central nervous system prophylaxis was 
administered earlier, with greater frequency and for a 
more prolonged period in pediatric trials and the 
duration of maintenance therapy is shorter in some 
adult trials.
23-25
 A more accurate administration of 
therapy in pediatric Institutions may also play a role, 
due to a peculiar attitude of pediatricians concerning 
the need to maintain the doses and schedules 
prescribed, and a possibly better compliance of 
adolescent patients treated in a pediatric facility.  
 
Results of Treatment of Adolescents with ALL by 
Pediatric Groups. The outcome of adolescents with 
ALL worldwide has significantly improved over time. 
Barry et al. reported the outcome of adolescents treated 
in the Dana-Farber Cancer Institute (DFCI) ALL 
Consortium Protocols conducted from 1991 and 
2000.
26
 A total of 844 patients aged 1 to 18 years, with 
newly diagnosed ALL were enrolled into two 
consecutive DFCI-ALL Consortium Protocols. 
Outcomes were compared in three age groups: children 
aged 1 to 10 years (n = 685), young adolescents aged 
10 to 15 years (n = 108), and older adolescents aged 15 
to 18 years (n = 51). With a median follow-up of 6.5 
years, the 5-year EFS for those aged 1 to 10 years was 
85%, compared with 77% for those aged 10 to 15 
years, and 78% for those aged 15 to 18 years. There 
was no difference in the rate of treatment-related 
complications between the 10- to 15-year and 15- to 
18-year age groups. The 5-year EFS of 78% is superior 
to published outcomes for similarly aged patients 
treated with other pediatric and adult ALL regimens.  
Nachman et al. reported the results of the CCG1961 
trial including AYA up to 21 yr.
27
 The EFS and overall 
survival (OS) rates were 71.5% and 77.5%, 
respectively. Rapid responder patients randomly 
assigned to augmented therapy had a 5-year EFS of 
81.8% vs 66.8% for patients receiving standard 
therapy, but 1 versus 2 interim maintenance and 
delayed intensification courses had no significant 
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impact on EFS. A WBC count over 50x109/L was an 
adverse prognostic factor. Given the excellent 
outcomes achieved with this chemotherapy there seems 
to be no role for the routine use of stem cell 
transplantation (SCT) in first remission.  
In turn, the results of the total therapy studies 
XIIIA, XIIIB, XIV 1 and XV from St Jude Children’s 
Research Hospital in the US including 963 pediatric 
patients, 89 of whom were older adolescents (aged 15 
to 18 yr.), have been published.
28
 In the first three 
studies the 44 older adolescents had a significantly 
poorer EFS and OS than the 403 younger patients. On 
the contrary, in study XV (that included the level of 
MRD to guide treatment, with featured intensive 
methotrexate, vincristine, glucocorticoid and 
asparaginase and early triple intrathecal chemotherapy 
for higher risk ALL) the EFS of 45 older adolescents 
was 86.4%, similar to 87.4% for the 453 younger 
children. The OS was also comparable (87.9% vs. 
94.1%, respectively). The authors concluded that older 
adolescents with ALL can be cured with risk-adjusted 
intensive chemotherapy without SCT. 
 Data from the Nordic NOPHO ALL92 protocol 
showed an EFS lower for patients >10 yr with B-
precursor ALL and WBC<50x10
9
/L (71% vs. 83%). 
Interestingly, for adolescents remaining in remission 
the mean WBC count during maintenance therapy was 
correlated with the risk of relapse, being this risk more 
pronounced in adolescents than in non-adolescents.
29
 
Thus, compliance to maintenance therapy may 
influence the risk of relapse in adolescents with ALL. 
In summary, with modern approaches of treatment 
of ALL with pediatric-based protocols prognosis of 
adolescents cannot be considered unfavorable since, 
hopefully, the improvement of pediatric patients can be 
translated to young adults. This concept has led some 
groups
30
 to perform a treatment reduction, on the basis 
of rapid clearance of MRD by the end of induction 
therapy, also in young adults (up to 25 yr) with 
standard-risk ALL . 
 
Pediatric-inspired and Unmodified Pediatric 
Treatments in Young Adults. Prospective Studies. 
Several prospective clinical trials using pediatric 
regimens for adults have been published (Table 3) or 
are currently ongoing. These studies are divided into 
two types according to their regimens and patients: a 
pediatric-inspired protocol planned by dose reduction 
of a pediatric protocol for adults up to 50 or 60 yr, and 
an unmodified pediatric protocol for AYA up to 30-40 
years.  
Pediatric-inspired protocols: The French GRAALL 
group reported the results of the pediatric-inspired 
GRAALL-2003 study including 215 patients aged 15-
60 years.
31
 In this study there was an 8.6-fold, 3.7-fold  
Table 3. Prospective studies in adolescents and young adults with 









USA (36) DFCI 91-01, 95-01 15-18* 51* 94 78 
Spain (34) PETHEMA ALL-96  15-18 35 94 60 
  
19-30 46 100 63 
France (31) GRAALL-2003  15-45 172 95 58 
USA (37) DFCI 18-50 74 82  72.5** 
Canada (33) Modified DFCI 17-71 68 85  65*** 





HOVON 70 17-39 54 91  66** 
* Results restricted to adolescents; **Estimated at 2 years; *** 
Overall survival. **** Disease-free survival. 
 
and 16-fold increase in cumulative doses of 
prednisone, vincristine and asparaginase, respectively, 
compared with the previous adult-based LALA-94 
protocol, although the GRAALL-2003 trial retained 
some adult options, such as allogeneic SCT for patients 
with high-risk ALL. The CR rate was 93.5%, and at 42 
months the EFS and OS rates were 55% and 60%, 
respectively. The CR rate, EFS and OS compared 
favorably with the previous LALA-94 experience. It is 
of note, however, that in patients over 45 yr there was a 
higher cumulative incidence of chemotherapy-related 
deaths (23% vs. 5%) and deaths in first CR (22% vs. 
5%), although the incidence of relapse remained stable 
(30 vs. 32%). The results of this study suggest that the 
pediatric-inspired therapy is feasible in young adults 
with ALL in whom the outcome clearly improves at 
least until the age of 45 yr. 
The HOVON Group published the results of a study 
in adults with ALL up to the age of 40 yr.
32
, inspired by 
a pediatric regimen (FRALLE approach for high-risk 
ALL), including intensified treatment with allogeneic 
SCT. Allogeneic SCT was offered to the standard-risk 
patients with sibling donor and to all high-risk patients. 
Fifty-four patients were included, with a median age of 
26 yr. Complete remission was achieved in 49 patients 
(91%), of whom 33 (61%) completed treatment as 
scheduled. Side effects primarily consisted of 
infections and occurred in 40% of patients. With a 
median follow-up of 32 months, the estimated EFS was 
66% and OS 72% at 24 months. In turn, the Princess 
Margaret Hospital used a modified Dana-Farber 
Cancer Institute pediatric protocol in 68 adult patients 
(17 to 71 years), with a CR rate of 85% and 3-year OS 
and DFS of 65% and 77%, respectively.
33 
Unmodified pediatric protocols: The Spanish 
PETHEMA study was the first trial to compare the 
results of the unmodified pediatric protocol ALL96 in 
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adolescents (15-18yr., n=35) and young adults (18-30 
yr., n=46) with standard-risk (SR) ALL.
34
 Both groups 
were comparable for the main clinical and biologic 
characteristics of ALL. The CR rate was 98% and after 
a median follow-up of 4.2 yr., 6-year EFS and OS were 
61% and 69%, with no differences between adolescents 
and young adults. No significant differences were 
observed in the timing of treatment delivery, although 
the hematologic toxicity in consolidation and 
reinforcement cycles was higher in young adults than 
in adolescents. These results suggest that unmodified 
pediatric protocols can be efficiently and safely 
employed in adult patients with SR ALL, at least up to 
the age of 30 yr. Similarly, an Australian study has 
recently reported the results of the FRALLE-93 
pediatric protocol in 40 AYA up to 45 years, with no 
treatment-related mortality and an OS probability of 




However, until recently, the efficacy of a fully 
pediatric protocol for AYA with high-risk ALL has not 
been analyzed. The Japan Adult Leukemia Study 
Group (JALSG) conducted a phase 2 trial in which 129 
patients aged 15 to 24 with BCR-ABL-negative ALL 
were treated with the same protocol developed for 
children with ALL by the Japan Association of 
Childhood Leukemia Study (JACLS). The CR rate was 
94% and the 5-year DFS and OS rates were 67% (95% 
CI 58–75%) and 73% (95% CI 64–80%), 
respectively.
36
 Severe adverse events frequently 
occurred but the frequency was similar to that observed 
in children treated with the same protocol. Only 
insufficient maintenance therapy significantly 
worsened the DFS. 
The DFCI Combined Adult/Pediatric
 
ALL 
Consortium has applied a pediatric protocol for adults 
aged 18-50 years.
37
 Specifically, the investigators used 
an extended course of asparaginase for 30 weeks. The 
results in 74 patients have shown a CR rate of 82% 
with promising 2-year EFS and OS probabilities of 
72.5% and 73.2%, respectively. This study proved that 
extended asparaginase treatment was feasible in adults, 
and the drug-related toxicity was manageable, although 
the incidence of pancreatitis (13%) and 
thrombosis/embolism (19%) was a matter of concern. 
The University of South California group
38
 used an 
augmented BFM pediatric regimen with eight doses of 
pegylated asparaginase to treat adults with ALL aged 
19-57 years (median 33), with a 3-year projected EFS 
of 65%. Toxicity attributable to asparaginase was 
frequent but manageable. However, older patients 
showed significantly less tolerance to asparaginase, 
vincristine and steroids compared to children or 
adolescents. In the FRALLE group from France 30 
Philadelphia chromosome-negative adult ALL patients 
16 to 57 years of age were treated in the FRALLE 2000 
protocol consisting of a prednisone pre-phase and a 4-
drug induction including asparaginase, consolidation, 
delayed intensification and maintenance chemotherapy. 
The 4-yr DFS was 90% vs. 47% in matched historical 
controls.
39 
The undergoing U.S. intergroup trial C10403 
(available at www.clinicaltrials.gov. NCT00558519) 
has been developed to examine and describe results 
among AYA with newly diagnosed ALL, treated using 
a successful Children’s Oncology Group regimen 
(COG ALL0232), which give rise to 78% survival rate 
for older adolescents aged 16–21 years. Individuals 
aged 16–39 with newly diagnosed ALL are eligible for 
participation.
40
 This trial will test the feasibility of 
treating young adults up to the age of 40 with a 
pediatric regimen, assess adherence by patients and 
adult oncologists, and describe the toxicities observed. 
A component of this trial will analyze issues based on 
demographics, psychosocial characteristics, and 
pretreatment features of the disease that are unique to 
the AYA population. The results of this trial will be 
compared with patients up to 29 years of age who were 
enrolled and treated by pediatric oncologists on the 
COG AALL0232 study (now closed to accrual). The 
goal of this trial is to demonstrate that the adult cancer 
cooperative groups can deliver a “true pediatric’’ 
regimen to AYA patients and achieve similar 
outcomes.  
In recent years, the MRD research has been 
incorporated to the therapeutic trials of adult AL, and it 
has been shown that a subgroup of patients with good 
MRD clearance can be successfully treated without 
SCT.
41-43
 Although these trials incorporate elements of 
pediatric protocols, no specific data on the AYA 
subpopulation were presented to date. 
 
Allogeneic Stem Cell Transplantation (SCT) in 
AYA. The role of allogeneic SCT in AYA is not 
clearly defined, and there are no prospective trials to 
assess the role of allogeneic SCT specifically in this 
population. An older retrospective study, from 1995, 
included patients between the ages of 15–45, from the 
International Bone Marrow Transplant Registry, and 
showed no survival advantages compared with 
chemotherapy alone. Transplanted patients had lower 




The largest published study evaluating the role of 
allogeneic SCT in ALL was a joint effort of Medical 
Research Council (MRC) in Great Britain and Eastern 
Cooperative Oncology Group (ECOG).
45
 This trial 
enrolled nearly 2000 ALL patients and 234 patients 
younger than 20 years of age. Based on this trial, there 
was an improvement in the 5-year OS of all patients 
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(53% vs. 45%) and standard-risk patients with 
Philadelphia-negative ALL (62% vs. 52%). The 10-
year cumulative relapse rate was 24% when allogeneic 
SCT was utilized versus 49% when patients were 
treated with chemotherapy alone or autologous SCT. 
However, there was no significant survival advantage 
in the high-risk group (41% vs. 35%) (P = 0.2). The 
high transplant-related mortality in this group (36%) 
offset the lower relapse rate in the high-risk group. One 
of the major limitations of this study was the use of 
adult regimens in treating AYA. A meta-analysis from 
13 studies including 2962 patients, excluding 
Philadelphia chromosome-positive patients, showed a 
survival benefit for having a matched sibling donor for 
patients < 35 years of age (OR = 0.79; 95% CI, 0.70-
0.90, P = .0003) but not for those ≥ 35 years of age 
(OR = 1.01; 95% CI, 0.85-1.19, P = .9) and concluded 
that matched sibling donor myeloablative SCT 
improves survival only for younger patients, with an 
absolute benefit of approximately 10% at 5 years.
46
 
Improved chemotherapy outcomes and reduced non-
relapse mortality associated with allogeneic SCT may 
change the relative effects of these treatments in the 
future. A recently published retrospective study 
compared changes in survival after myeloablative SCT 
for ALL among children (n = 981), AYA (n = 1218), 
and older adults (n = 469) who underwent 
transplantation over 3 time periods: 1990 to 1995, 1996 
to 2001, and 2002 to 2007. Survival improved over 
time in AYA and paralleled that seen in children and 
was primarily related to lower rates of early treatment-
related mortality in the most recent era, whereas 
relapse rates did not change over time.
47
 A comparative 
study of outcomes of children and AYA undergoing 
allo-HCT for B-ALL showed that AYA had a 
significantly inferior survival and a greater 
transplantation-related mortality compared with 
children aged <13 years, but with no differences in 




Therefore, the use of allogeneic SCT in standard-
risk AYA patients remains controversial and warrants 
further investigation.
49
 As MRD analysis plays a 
central role in defining the indications for allo SCT 
using pediatric-type programs in adult patients
50
, future 
studies should focus on more precisely identifying 
poor-risk features, such as disease genomics and host 
pharmacogenomics, refining MRD measurements, 
improving unrelated donor matching, reducing MRD 
prior to alloHSCT, and developing post-alloHSCT 
humoral and cellular therapy approaches.
51 
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